drugset
drugset / Trial / NCT02837146

Ultrasound as Imaging Biomarker of Early Response to Tocilizumab and Methotrexate in Very Early Rheumatoid Arthritis

NCT02837146 ↗

Phase 3 Unknown 45 enrolled Maria Stoenoiu
NaSingle-groupOpen-labelTreatment

Summary

This study is aimed at assessing the kinetics of the ultrasound (US) response in DMARD-naive very early rheumatoid arthritis (RA) patients treated with tocilizumab (TCZ) and methotrexate (MTX).

Timeline

Start
2015-12
Primary completion
2018-12
Completion
2019-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Methotrexate Small molecule 15 mg —
Subject Methotrexate Small molecule 20 mg —
Subject Tocilizumab Monoclonal antibody 162 mg Subcutaneous

Indications

rheumatoid arthritis